ライフサイエンスコーパス: double-blind study

1 pen appendectomy in a prospective randomized double blind study.

2 1) for 12 months in a phase II, multicentre, double-blind study.

3 lacebo with MTX (placebo group), in a 2-year double-blind study.

4 perphenazine, with several newer drugs in a double-blind study.

5 d to receive colchicine or methotrexate in a double-blind study.

6 , 10 to 28 mm) in a prospective, randomized, double-blind study.

7 This was a multicenter, randomized, double-blind study.

8 e enrolled in this prospective, multicentre, double-blind study.

9 fter one month off of hormone treatment in a double-blind study.

10 nate therapy after 1 month off therapy, in a double-blind study.

11 this prospectively in a larger, randomized, double-blind study.

12 cirrhosis were included in this prospective, double-blind study.

13 e mania who entered a 3-week parallel group, double-blind study.

14 nts) once daily at bedtime for 12 weeks in a double-blind study.

15 nrolled in a randomized, placebo-controlled, double-blind study.

16 es daily (n=83) for 5 days in a multicenter, double-blind study.

17 R) was recently established in a prospective double-blind study.

18 enrolled in this randomized parallel group, double-blind study.

19 alone to the other nostril in a randomized, double-blind study.

20 IVIg or placebo, monthly, for 3 months in a double-blind study.

21 lovir (ganciclovir group) until day 100 in a double-blind study.

22 us delivery of EVs, CMP-EVs and placebo in a double-blind study.

23 placebo (n=83) for 24 weeks in a randomized, double-blind study.

24 studied in a placebo-controlled, randomized, double-blind study.

25 n a phase 2, randomized, placebo-controlled, double-blind study.

26 r placebo (n=15) for 14 days in a randomized double-blind study.

27 stage IV metastasis tissue microarrays in a double-blind study.

28 ncer positive and negative samples through a double-blind study.

29 ion in Alsace) is a prospective, randomized, double-blind study.

30 model of acute inflammation) or placebo in a double-blind study.

31 e 2.5 mg daily or tamoxifen 20 mg daily in a double-blinded study.

32 Randomized, placebo-controlled, double-blinded study.

33 t cancer were randomized to two multicenter, double-blind studies (088001 and 088006).

34 Of 3,964 patients in double-blind studies, 1,427 had a history of atrial fibr

35 In this 24-week multicenter, randomized, double-blind study, 1,220 type IIa or IIb hyperlipidemic

36 At screening of the double-blind study, 101 patients (83.5%) were taking an

37 METHODS AND In a multicenter, randomized, double-blind study, 123 patients with stable coronary ar

38 In this phase 2, double-blind study, 124 subjects with biopsy-proven NASH

39 In this double-blind study, 127 patients with psoriatic arthriti

40 In a double-blind study, 148 clinically stable, overweight (b

41 In a randomized, double-blind study, 17 healthy human subjects received o

42 In this double-blind study, 17 HIV-infected individuals with vir

43 In a parallel-group, double-blind study, 179 patients hospitalized for acute

44 In this double-blind study, 1797 patients with hypertension (mea

45 In this phase 1b/2a, double-blind study, 183 healthy preterm and full-term in

46 In the double-blind study, 20 of the 29 patients in the recombi

47 In the double-blind study, 21 of the 26 patients who received p

48 , randomized, flexible-dose, parallel-group, double-blind study, 280 men with erectile dysfunction fo

49 In this randomized double-blind study, 399 students either wrote about thei

50 In this 4-week double-blind study, 404 patients were randomized to 20 m

51 In this double-blind study, 420 postmenopausal women were random

52 In this randomized double-blind study, 43 HIV-1-infected patients received

53 In a parallel-group, double-blind study, 52 (14 men, 38 women) healthy normal

54 In this multicenter, double-blind study, 615 patients with first-ever unprovo

55 In a double-blind study, 628 patients with baseline LDL-C 145

56 In this 24-week, double-blind study, 672 patients underwent randomization

57 receive fluoxetine or placebo in a 12-week, double-blind study; 73% (59 of 81) of the patients in ea

58 In a double-blind study, 80 depressed patients were randomize

59 In this double-blind study, 87 immunocompromised patients with c

60 In a randomized, within-subject, double-blind study, 88 healthy men and women received a

61 In this double-blind study, 97 HIV-infected patients who had rec

62 In this double-blind study, adult patients with hyperuricemia an

63 In a multicenter, double-blind study, adults (ages 18-64 years) with treat

64 In this double-blind study, adults with CABP of Pneumonia Outcom

65 In this randomized, double-blind study, adults with HDM-associated allergic

66 In a 3 d double-blind study and in a 10 d repeated stimulation st

67 se who responded to treatment then entered a double-blind study and were randomly assigned to receive

68 patients who were enrolled, 400 entered the double-blind study, and 370 received at least one postba

69 Placebo-controlled, double-blinded studies are required to confirm our findi

70 This double-blind study assessed immunogenicity, lot consiste

71 A randomized, double-blind study assessed the efficacy and safety of p

72 plus anakinra (100 mg/day) for 6 months in a double-blind study at 41 centers in the US.

73 We performed a double-blind study at 49 hospitals in Europe and Israel,

74 We performed a prospective, randomized, double-blind study at 5 level 1 trauma centers.

75 multicentre, randomised, placebo-controlled, double-blind study at 66 hospitals and clinics in Austra

76 in a randomized (dupilumab vs placebo; 2:1), double-blind study at Atopic Dermatitis Research Network

77 This 12-month double-blind study attempted remission induction using s

78 In a phase 3, randomized, double-blind study (ATTRibute-CM [Efficacy and Safety of

79 In this double-blind study children with PA were randomized to r

80 In a double-blind study, children and adolescents with ADHD (

81 For patients who completed the 10-week double-blind study, clozapine was superior to haloperido

82 This 47-week, randomized, double-blind study compared flexibly dosed olanzapine (5

83 This multicenter, randomized, double-blind study compared mibefradil with placebo as a

84 This randomized, double-blind study compared olanzapine, quetiapine, risp

85 This randomized, double-blind study compared sildenafil at doses of 5, 20

86 This double-blind study compared the effect of palifermin wit

87 This multicenter, randomized, double-blind study compared the efficacy and safety of i

88 This randomized double-blind study compared the efficacy and safety of i

89 andomized, placebo-controlled, double-dummy, double-blind study compared the magnitude and duration o

90 A 6-week, randomized, double-blind study compared whole-body hyperthermia with

91 A randomized double-blind study comparing aprepitant versus dexametha

92 CANOPY-1 was a phase III, randomized, double-blind study comparing canakinumab (200 mg subcuta

93 3 patients were enrolled in this randomized, double-blind study comparing losartan (50 to 100 mg once

94 mary sclerosing cholangitis in a randomized, double-blind study comparing ursodiol (13 to 15 mg per k

95 A 6-week, randomized, double-blind study conducted between February 2013 and M

96 xib Trial (REACT) was a phase 3, randomized, double-blind study conducted in 160 centers across the U

97 X-ACT was a phase III, randomized, double-blind study conducted in 24 centres (Germany), wh

98 NG, AND PATIENTS: Single-center, randomized, double-blind study conducted in a level 3 pediatric inte

99 In a double-blind study conducted in the winter, 30 healthy m

100 scertainment bias, and only 2 studies with a double-blinded study design have been conducted.

101 hat involves randomized, placebo-controlled, double-blind studies designed to maximize statistical po

102 In a double-blind study, desipramine or placebo was added for

103 In this randomised, double-blind study, done at 87 sites in 13 countries, we

104 ent groups who received at least one dose of double-blind study drug.

105 After participating in a 12-week multicenter double-blind study during which they received placebo or

106 In this randomised, double-blind study eligible patients were aged 36-70 yea

107 In this phase 3 double-blind study, eligible participants were children

108 The primary double-blind study end points were changes between basel

109 enter, 6-mo, randomized, placebo-controlled, double-blind study enrolled 150 healthy females [18-65 y

110 This pivotal phase 3, randomized, double-blind study enrolled adults into 3 age groups (>=

111 multicenter, randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of

112 is randomized, phase 2b, placebo-controlled, double-blind study evaluated the efficacy and safety of

113 This randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of

114 This double-blind study evaluated treatment with either a sin

115 A randomized, placebo-controlled, double-blind study evaluating 36 patients with mild-to-m

116 iomarkers, a placebo controlled, randomized, double blinded study in active steroid dependent and ste

117 We conducted separate randomized, double-blind studies in 38 centers in North America and

118 We conducted a multicenter, randomized, double-blind study in 394 healthy adults.

119 f this prospective, multicenter, randomized, double-blind study in cardiac transplant patients were:

120 61803534 was studied in a phase 1 randomized double-blind study in healthy human volunteers to assess

121 We conducted a prospective, randomized, double-blind study in healthy, preterm infants (gestatio

122 c Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic

123 ulticenter, prospective, placebo-controlled, double-blind study in which 564 high-risk patients under

124 multicenter randomized, placebo-controlled, double-blind study in which 78 HIV-infected, ART-naive s

125 We conducted a randomized, double-blind study in which 87 patients between 8 and 40

126 This study was conducted as a double-blind study in which eight groups of middle-aged

127 Part one was a double-blind study in which patients with symptomatic, a

128 We conducted a double-blind study in which previously untreated adults

129 t the results of a multinational randomized, double-blind study, in which postmenopausal women with o

130 AMBITION was a multicentre, randomised, double-blind study, in which treatment-naive patients wi

131 This prospective, multicenter, randomized, double-blind study included 397 patients who were random

132 This randomized, double-blind study included 76 EFI patients who were ran

133 s a randomised, phase 1, placebo-controlled, double-blind study, including participants who were HIV

134 In randomized, double-blind studies, infiltration of the neurovascular

135 In a 6-week double-blind study, inpatients with a recent exacerbatio

136 ER PFO Occluder to Medical Management) was a double-blind study investigating migraine characteristic

137 This was a double-blind study investigating the effects of three do

138 This randomized, double-blind study involved three antiretroviral regimen

139 In this randomized, double-blind study involving 10 days of treatment and 30

140 In this double-blind study involving 142 patients with metastati

141 d an international, multicenter, randomized, double-blind study involving 1862 patients with ongoing

142 population studies [PS]) were evaluated in a double-blind study involving 284 methicillin-resistant S

143 ed a 2-year, placebo-controlled, randomized, double-blind study involving 87 elderly men with low lev

144 In this phase 2, double-blind study, kidney transplant recipients with BK

145 eted a paradigm isolating these systems in a double-blind study measuring dopamine synthesis with [(1

146 ingle-blind placebo on day -1 (baseline) and double-blind study medication (placebo [n = 12] or lixiv

147 d patients who received at least one dose of double-blind study medication and who had both a baselin

148 mly assigned to treatment and exposed to the double-blind study medication.

149 In 2 phase III, randomized, double-blind studies, men and women with HIV-associated

150 In a randomized double-blind study (n = 127), science faculty from resea

151 In the double-blind study, none of the 12 lesions in the six pa

152 alth Initiative study in 2002, a prospective double-blind study, noted an increased risk of breast ca

153 In a double-blind study, nucleos(t)ide-naive patients with hi

154 il, administered as needed in two sequential double-blind studies of men with erectile dysfunction of

155 atic review and meta-analysis of randomised, double-blind studies of oral and topical pharmacotherapy

156 We performed a prospective, multicenter, double-blind study of 115 healthy, postmenopausal women

157 randomized, prospective, placebo-controlled, double-blind study of 122 patients at 17 centers in Euro

158 In a randomized placebo-controlled double-blind study of 162 HIV-negative RV144 vaccine rec

159 We performed a double-blind study of 165 patients with primary biliary

160 In a double-blind study of 40 patients with malignant melanom

161 We performed a double-blind study of 57 treatment-naive patients with H

162 multicenter, randomized, placebo-controlled, double-blind study of 58 patients who were treated every

163 A double-blind study of 672 patients with OA of the knee w

164 We performed a double-blind study of 78 patients with NASH at 9 centers

165 COU-AA-301 is a randomized, double-blind study of AA (1,000 mg every day) plus P (5

166 e then performed a randomized placebo-phase, double-blind study of alirocumab 150 mg administered sub

167 lled in this randomized, placebo-controlled, double-blind study of AZ 100 mg on all-cause mortality.

168 lled in this randomized, placebo-controlled, double-blind study of azimilide 100 mg on all-cause mort

169 conducted a randomized, placebo-controlled, double-blind study of clarithromycin in patients with AI

170 ors conducted an 8-week, placebo-controlled, double-blind study of E-EPA in 30 female subjects meetin

171 ACh response was determined in a randomized double-blind study of eight healthy subjects, who were s

172 of <1 year's duration had been enrolled in a double-blind study of minocycline (100 mg twice daily) v

173 Data were obtained from a randomized, double-blind study of patients with moderate-to-severe f

174 Randomized, double-blind study of patients with schizophrenia assign

175 STAND is a phase 3, multicentre, randomised, double-blind study of patients with sickle cell disease

176 in Intolerant Subjects) trial was a 12-week, double-blind study of randomized patients (2:2:1:1) to e

177 ts (n = 105) were enrolled into a randomized double-blind study of rimantadine treatment of experimen

178 ffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and halop

179 acebo-controlled, dose-response, randomized, double-blind study of the effect of vitamin D on calcium

180 A randomized, double-blind study of valaciclovir for suppression of re

181 Here we report the results of double-blinded studies of the performance of paper-based

182 Phase 2 randomized, controlled, double-blinded study of 4 antiretroviral regimens used a

183 00 cases) that participated in a randomized, double-blinded study of intracoronary RT completed a que

184 We measured vigour in a placebo-controlled, double-blinded study of trihexyphenidyl (THP), a muscari

185 BS management, we performed this controlled, double blind study on patients with IBS who were randomi

186 In a Phase II double-blind study, orally administered interferon alpha

187 lysis of a phase 3, randomised, multicentre, double-blind study, patients aged 6 months to 17 years w

188 In a large placebo-controlled, double-blind study, patients ages 6-16 with ADHD, any su

189 In a double-blind study, patients received placebo or a probi

190 In this double-blind study, patients with DSM-IV generalized anx

191 In this multicenter, investigator-initiated, double-blind study, patients with first-ever unprovoked

192 In this double-blind study, patients with type 2 diabetes (eithe

193 (n = 43) or autologous stools (n = 19) in a double-blind study, performed from December 2015 through

194 (n = 43) or autologous stools (n = 19) in a double-blind study, performed from December 2015 through

195 eligible to receive open-label FMT after the double-blind study period.

196 objective of the large-scale randomized and double-blinded study presented in this paper was to dete

197 This double-blind study randomized 346 pregnant women with HI

198 This 6-month, double-blind study randomized patients with moderate to

199 This 3-week, multicenter, double-blind study randomly assigned 262 bipolar disorde

200 Recent large randomized double-blind studies show the efficacy of these agents i

201 In a randomized, double-blind study, sildenafil 100 mg or placebo was giv

202 In two identical phase 3, double-blind studies (study 04, 652 participants; study

203 In this double-blind study, subjects undergoing HSCT with fluoro

204 In this multicenter, double-blind study, symptomatic HIV-infected children 3

205 This randomized, double-blind study tested the hypothesis that rofecoxib,

206 onary artery lesions) trial is a randomized, double-blind study that compared sirolimus-eluting and b

207 tients were part of the URICO-ICTUS trial, a double-blind study that compared the administration of u

208 Phase 2 was a double-blind study that randomly assigned patients (1:1:

209 In this 8-wk double-blind study the hemodialysis patients were random

210 In a placebo-controlled, double-blind study, the authors investigated the efficac

211 In a randomized, double-blind study, the efficacy of scorpion-specific F(

212 In the double-blind study, there were no significant difference

213 conducted a multicenter, placebo-controlled, double-blind study to confirm these results in cardiac-t

214 We performed a prospective, randomized, double-blind study to determine whether calcium and calc

215 (mean age, 70.7 years) were randomized in a double-blind study to either active estrogen patch or id

216 s work used a multi-modal sensing glove in a double-blind study to enable sensitive monitoring of med

217 We performed a crossover, randomized, double-blind study to evaluate HT bioavailability in HT-

218 Fontan procedure, we performed a randomized, double-blind study to evaluate the impact of an incision

219 ate to severe disease, randomized in a 13-wk double-blind study to placebo (n = 73) or salmeterol/flu

220 real circulation were randomly assigned in a double-blind study to receive high-dose aprotinin, epsil

221 ith anxiety from an LTI were randomized in a double-blind study to receive MDMA (125 mg, n = 13) or p

222 mbricoides-infected subjects randomized in a double-blind study to receive two doses of either albend

223 We conducted a randomized controlled, double-blind study to test the hypothesis that hypoxia d

224 A randomized double-blinded study to define the activity of IM862 in

225 n a randomized, cross-over, sham-controlled, double-blind study using EEG to measure the offline effe

226 We undertook a double-blind study using stereological cell counting met

227 Here, in a double-blinded study using objective spatiotemporal gait

228 and of sulindac, as a positive control, in a double-blind study, using azoxymethane-induced colonic a

229 ating esophageal candidiasis was tested in a double-blind study versus oral fluconazole.

230 S: A prospective, single-center, randomized, double-blind study was conducted at the Brazilian Center

231 A phase III, randomized, double-blind study was conducted by the North Central Ca

232 This randomized, double-blind study was conducted in 142 sites in 17 coun

233 A randomized, placebo-controlled, double-blind study was conducted in healthy adults aged

234 A randomized, crossover, double-blind study was conducted in healthy and MetS adu

235 A Phase II, multicenter, randomized, double-blind study was conducted in the USA (NCT03682770

236 A randomized, double-blind study was conducted to assess the anti-HIV

237 A multicenter, double-blind study was conducted to determine rates of s

238 A randomized, double-blind study was conducted to evaluate the pharmac

239 An 8-week double-blind study was conducted with 28 patients who we

240 This double-blind study was designed to assess the effects of

241 A 12-week, randomized, double-blind study was designed to compare gabapentin (1

242 ndomized, parallel-group, placebo-controlled double-blind study was performed at university and commu

243 A prospective double-blind study was performed comparing VHC to vancom

244 The aim of this prospective randomized double-blind study was to compare the efficacy and safet

245 The purpose of this double-blind study was to evaluate the efficacy of the L

246 This randomised, double-blind study was undertaken in 117 sites in North

247 A multicenter, randomized, double-blind study was undertaken in 2342 infants to eva

248 prospective, randomized, placebo-controlled, double-blinded study was performed in 6 academic medical

249 Recently, a prospective, double-blinded study was performed to help settle the de

250 VA-3, a multicentre, multinational, phase 3, double-blind study, was done at 206 investigational site

251 In a multicenter randomized double-blind study we demonstrated that Qiliqiangxin (QL

252 In a cross-sectional, placebo-controlled, double-blind study we examined the effect of 10-12 y of

253 In two multisite, randomized, double-blind studies, we compared a single application o

254 ive, consecutively enrolled, broad-spectrum, double-blind studies, we developed an objective eye-trac

255 In four multicenter, randomized, double-blind studies, we randomly assigned patients with

256 multicenter, randomized, placebo-controlled, double-blind study, we assign 597 subjects with psoriasi

257 In this randomized, double-blind study, we assigned 14,671 patients to add e

258 In this randomized, double-blind study, we compared apixaban (at a dose of 1

259 In a randomized, double-blind study, we compared lorazepam with placebo f

260 In this randomized, double-blind study, we compared the effect of 6 months o

261 In this randomized, double-blind study, we compared two doses of apixaban (2

262 In this randomised, placebo-controlled, double-blind study, we enrolled adults (aged 18-80 years

263 In this randomised, placebo-controlled, double-blind study, we enrolled patients aged 18 years o

264 multicenter, randomized, placebo-controlled, double-blind study, we evaluated alefacept as a treatmen

265 In a double-blind study, we evaluated subjects with the amnes

266 In this phase 3, multicenter, randomized, double-blind study, we evaluated the efficacy and safety

267 In a double-blind study, we randomly assigned 1049 consecutiv

268 In this double-blind study, we randomly assigned 1088 patients t

269 In this double-blind study, we randomly assigned 2392 young wome

270 In a multicenter, double-blind study, we randomly assigned 255 patients wi

271 In a placebo-controlled, double-blind study, we randomly assigned 32 healthy volu

272 In this phase 3, double-blind study, we randomly assigned 443 patients wi

273 In a substudy of a larger double-blind study, we randomly assigned 602 healthy men

274 the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1

275 In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 rat

276 In this pilot double-blind study, we study 30 HIV-infected subjects on

277 Here, in a preregistered, double-blinded study, we examined how pharmacologically

278 Patients who completed the double-blind study were then entered into a 1-year open-

279 Double-blind studies with sufficient power to resolve th

280 l 2 x 2 x 2, randomized, placebo-controlled, double-blind study with 3 active treatments: folic acid

281 In this double-blind study with a 2-by-2 factorial design, we ra

282 rative Study was a prospective, multicenter, double-blind study with consecutive enrollment of patien

283 This was a phase 1, randomized, double-blind, study with 2 parts.

284 In a double-blinded study with 132 pond water samples, we est

285 A prospective double-blinded study with preset sonographic criteria ha

286 Drug-Eluting Stent Below the Knee-Randomised Double-Blind Study [YUKON-BTX]; NCT00664963).